Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Research And Development Expense of $12.71 million for the year ending 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +0.5% in Research And Development Expense from 2024 to 2025.
- This data is from CATALYST PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), CATALYST PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 149.3%.
- Historical annual values: Fiscal year 2025: $12.71 million | Fiscal year 2024: $12.65 million | Fiscal year 2023: $93.15 million | Fiscal year 2022: $19.79 million | Fiscal year 2021: $16.94 million | Fiscal year 2020: $16.50 million | Fiscal year 2019: $18.84 million | Fiscal year 2018: $19.92 million | Fiscal year 2017: $11.38 million | Fiscal year 2016: $11.37 million | Fiscal year 2015: $11.80 million | Fiscal year 2014: $10.12 million | Fiscal year 2013: $8.10 million | Fiscal year 2012: $2.66 million | Fiscal year 2011: $3.38 million | Fiscal year 2010: $2.31 million | Fiscal year 2009: $5.10 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: